# Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

> **NCT06721871** · PHASE2 · RECRUITING · sponsor: **Napo Pharmaceuticals, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Microvillus Inclusion Disease
- Congenital Disorders
- Rare Diseases

## Interventions

- **DRUG:** Crofelemer Powder for Oral Solution
- **DRUG:** Placebo Powder for Oral Solution

## Key facts

- **NCT ID:** NCT06721871
- **Lead sponsor:** Napo Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-02
- **Final completion:** 2026-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721871, "Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06721871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*